The CE mark will take what it takes but the real win will come with the results of the trials, PanCO and OncoPaC-1. Making a realistic chance of recovery from Pancreatic Cancer (PC) will be the dramatic leverage. See the Annual Report. Currently PC has only a 1% chance of recovery with a 5% chance of surviving 5 years. What this device is looking like doing, providing a real %age chance of not only surviving longer but full recovery for others, will make this device invaluable and testable for a whole range of cancers. If it takes a few months to get there, who cares.
The CE mark will take what it takes but the real win will come...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
